Encouraging early data on S*BIO's pipeline

Singapore biotechnology firm S*BIO says that an oral presentation at the American Society of Hematology's 49th annual meeting, held in Atlanta, Georgia, on its novel and selective JAK2 inhibitor SB1518 highlighted its therapeutic potential for the treatment of myeloproliferative disorders.

Commenting on other news from the ASH meeting, Jan-Anders Karlsson, chief executive of the firm, said: "we are currently conducting Phase I clinical trials for SB939 in Canada and Singapore, and expect the initiation of Phase I trials in various centers in the USA. We are also delighted to report data on our Flt3-CDK inhibitor, SB1317." The novel potent inhibitor of FLT3 kinase and CDKs 1, 2 and 9, demonstrated therapeutic potential for the treatment of hematological malignancies. FLT3 is the most common mutated gene in acute myeloid leukemia.